ezetimibe

ezetimibe

美 　英

• 網絡依折麥布；依澤替米貝；依替米貝

例句

Merck and Schering did not begin such a trial until October 2005, three years after ezetimibe was approved.

在ezetimibe批準上市后三年，直到2005年10月，默克和先靈葆雅才開始這個試驗。

The lack of data about ezetimibe highlights an aspect of the drug approval system that even sophisticated patients may not understand.

ezetimibe數據資料的不足暴露了藥品審批制度的一個方面，即使是精明的病人可能都弄不明白。

For the interim doctors and patients are left with a quandary as to the efficacy and safety of ezetimibe.

因此目前對于醫生和患者來說，依析替林的有效性和安全性依然是個問題。

and the compound VII is reduced to a compound IX ezetimibe by a borane chiral reducing agent.

化合物VII經硼烷類手性還原劑還原為化合物IX依澤替米貝。

In this article, the mechanism, pharmacokinetics and advances in clinical application of ezetimibe are summarized.

本文綜述了依折麥布的作用機制、藥動學特性及其在臨床應用中的最新進展。

With little long-term data about ezetimibe's risks, scientists are scrambling to find an explanation for the seeming cancer link.

幾乎沒有關于ezetimibe風險的長期資料，科學家們正在爭先恐后的找尋它和癌癥有關系的緣由。

Still, the concerns about ezetimibe's potential risks and lack of effectiveness have discouraged some patients from using the medicine.

然而，對ezetimibe潛在危險性和效力不足的擔憂還是影響了病人使用該藥。

So ezetimibe remains heavily prescribed despite questions about both its effectiveness and whether it is linked to cancer.

所以盡管有對Ezetimibe有效性和是否致癌的疑問，但是它依舊有很多的處方量。

Dr. Jacks said Merck and Schering could not easily resolve the questions about ezetimibe's potential risks.

Jacks博士說，默克和先靈葆雅不太可能輕而易舉解決ezetimibe潛在風險性的問題。

But other scientists say they have a plausible explanation for why ezetimibe may cause cancer.

但是其他一些科學家說他們對為什么ezetimibe會引起癌癥有一個看似合理的解釋。

Ezetimibe and cancer: what is the risk?

依析替林和癌癥：誰更危險？

The New Cholesterol Absorption Inhibitor Ezetimibe and Its Clinical Advances on Combination with Statins

新型膽固醇吸收抑制劑依澤替米貝與他汀類聯合應用評價

The Selective Cholesterol Absorption Inhibitor-Ezetimibe

膽固醇吸收抑制劑——依折麥布

Ezetimibe, a new cholesterol absorption inhibitor

新型膽固醇吸收抑制劑依澤替米貝